Meet Dr. Sweis
Randy Sweis, MD specializes in the treatment of patients with genitourinary malignancies including bladder, kidney, prostate and testicular cancers. He is an expert in the use of leading-edge immunotherapies and novel investigational treatments. Dr. Sweis develops a personalized, multidisciplinary treatment plan for each of his patients.
An accomplished physician-scientist, Dr. Sweis' research is focused on enhancing the immune response against cancer. He translates laboratory findings to patient care using his expertise in developmental therapeutics and clinical pharmacology. He has an interest in developing biomarkers and investigating novel therapeutic strategies to improve the effectiveness of immunotherapy treatments.
Specialties
Areas of Expertise
Board Certifications
- Internal Medicine
- Medical Oncology
Memberships & Medical Societies
- American Association for Cancer Research
- Society for Immunotherapy of Cancer
- Bladder Cancer Advocacy Network
- American Society for Clinical Pharmacology and Therapeutics
- American Society of Clinical Oncology
- Sigma Xi
- American Association of Immunologists
Practicing Since
- 2013
Languages Spoken
- English
- Arabic
Medical Education
- University of Chicago Pritzker School of Medicine
Internship
- University of Michigan Hospital
Residency
- University of Michigan Hospitals & Health Ctrs.
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
- An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
- Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
- Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors
- Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
- A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors
- SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
- Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)
- Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
- A Study of PY314 in Subjects With Advanced Solid Tumors
- A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
- An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
- Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
- Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
- Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma
- Pembrolizumab and EDP1503 in Advanced Melanoma
- Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
- A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient